Immunovia Seeks New CFO to Drive US Market Expansion

Immunovia AB, a pioneering diagnostic company specializing in blood-based testing for early detection of pancreatic cancer, has announced its search for a new Chief Financial Officer (CFO) to support its commercialization efforts in the USA. The company's focus on the US market, the world's largest for pancreatic cancer detection, underscores its commitment to increasing survival rates through early detection.

As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial leadership needs are evolving. The launch of Immunovia's pancreatic cancer test in the USA creates a need for deeper expertise and relationships in the US diagnostics market as well as global capital markets. The company is seeking a CFO with diagnostics or med tech operating experience, a network of US industry contacts, and a track record of successfully communicating with capital markets across different geographies.

With this move, Karin Almqvist Liwendahl, the current CFO, will step down at the end of the first quarter of 2025. Karin has played a significant role in transforming Immunovia over the last three years, helping to streamline the organization, lower operating costs, and reduce cash burn. Her contributions have been invaluable in positioning the company for its US market entry.



In the interim period, financial leadership responsibilities will be assumed by Jeff Borcherding, CEO, and Immunovia finance team members. The new CFO will be instrumental in driving Immunovia's success in the US market, focusing on key performance indicators such as revenue growth, market penetration, operating costs, cash burn rate, and clinical performance.

The new CFO's role aligns with Immunovia's strategic goals for US market penetration and commercialization of its pancreatic cancer test. By leveraging industry experience, US market knowledge, and global capital markets expertise, the new CFO will be crucial in supporting Immunovia's mission to increase survival rates for patients with pancreatic cancer through early detection.

As Immunovia continues to grow and expand its reach, investors and capital markets will be eager to track the company's progress towards its strategic goals. The new CFO's focus on key performance indicators and effective communication with investors will be essential for maintaining investor confidence and securing the funding needed to support Immunovia's growth.